Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethylmorphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 8/20 | 0.79 |
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.79 |
| ▸ | OPRK1 known ✓ | P41145 | 4/20 | 0.79 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.79 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.79 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.79 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.71 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.79 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylmorphine SCHEMBL29845657 | 0.99 | OPRM1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL17747970 | 0.99 | OPRM1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL29392212 | 0.99 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL14516212 | 0.99 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL15653227 | 0.99 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL16922138 | 0.99 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL14611951 | 0.99 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL15757784 | 0.99 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL24971 | 0.99 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Ethylmorphine SCHEMBL18770594 | 0.99 | OPRD1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121455-A1 | OPIOID RECEPTOR ANTAGONIST CONJUGATE AND USE THEREOF | Shanghai Hanmai Bio-Pharma Co., Ltd. (CN) | 2021-04-29 | — | — | US | claimed |
| EP-3406614-A1 | OPIOID RECEPTOR ANTAGONIST CONJUGATE AND USE THEREOF | Shanghai Hanmai Bio-Pharma Co., LTD. (CN) | 2018-11-28 | — | — | EP | claimed |
| CN-104688767-B | Application of Antaole in preparing drug-relief medicine | 宁夏恩多芬科技有限公司 | 2017-10-24 | — | — | CN | claimed |
| CN-107033154-A | Opiate receptor antagonist conjugate and its application | 苏州派格生物科技有限公司 | 2017-08-11 | — | — | CN | claimed |
| CN-105193838-A | New technology of nitrous oxide quick-acting drug treatment | NINGXIA ENDORPHIN TECHNOLOGY CO LTD | 2015-12-30 | — | — | CN | claimed |
| CN-104688767-A | Application of Entonox in drug addiction treatment | NINGBO ENDORPHELLON TECHNOLOGY CO LTD | 2015-06-10 | — | — | CN | claimed |
| CN-104473927-A | Polyethylene glycol and medicine molecule conjugate and preparation method thereof | BEIJING JENKEM TECHNOLOGY CO LTD | 2015-04-01 | — | — | CN | claimed |
| US-20060110333-A1 | Composition for nasal absorption | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-25 | — | — | US | claimed |
| CN-1674903-A | Composition for transnasal absorption | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-09-28 | — | — | CN | claimed |
| EP-1535615-A1 | COMPOSITION FOR NASAL ABSORPTION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-01 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0214735-B1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION | Euroceltique S.A. (LU) | 1991-08-28 | — | — | EP | claimed |
| US-4834965-A | Controlled release pharmaceutical composition | EUROCELTIQUE, S.A. (LU) | 1989-05-30 | — | — | US | claimed |
| EP-0214735-A1 | Controlled release pharmaceutical composition | Euroceltique S.A. (LU) | 1987-03-18 | — | — | EP | claimed |
| US-11311533-B2 | Opioid receptor antagonist conjugate and use thereof | Shanghai Hanmai Bio-Pharma Co., Ltd. (CN) | 2022-04-26 | — | — | US | disclosed |
| US-11299587-B2 | Starting material, for bulk drug or additives for drug, and bulk drug or drug using same | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2022-04-12 | — | — | US | disclosed |
| US-20210363300-A1 | STARTING MATERIAL FOR BULK DRUG OR ADDITIVES FOR DRUG, AND BULK DRUG OR DRUG USING SAME | SANYO CHEMICAL INDUSTRIES, LTD. (JP) | 2021-11-25 | — | — | US | disclosed |
| EP-0227836-A1 | SUSTAINED RELEASING PATCH | TEIJIN LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0214735-A1 | Controlled release pharmaceutical composition | Euroceltique S.A. (LU) | 1987-03-18 | — | — | EP | disclosed |
| US-4167636-A | ANTITUSSIVE AGENT | CHINOIN GYOGYSZER ES VEGYESZETI (HU) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121455-A1 | OPIOID RECEPTOR ANTAGONIST CONJUGATE AND USE THEREOF | OPRL1, OPRM1, OGFR | OPRD1 5/4885OPRM1 2/4885OPRK1 4/4885 |
| US-11311533-B2 | Opioid receptor antagonist conjugate and use thereof | OPRL1, OPRM1, OGFR | OPRD1 5/4885OPRM1 2/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.